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Abstract Treatment with inotropic agents is one of the
most controversial topics in heart failure. Initial enthusiasm,
based on strong pathophysiological rationale and apparent
empirical efficacy, has been progressively limited by results
of controlled trials and registries showing poorer outcomes
of the patients on inotropic therapy. The use of these agents
remains, however, potentially indicated in a significant
proportion of patients with low cardiac output, peripheral
hypoperfusion and end-organ dysfunction caused by heart
failure. Limitations of inotropic therapy seem to be mainly
related to their mechanisms of action entailing arrhythmo-
genesis, peripheral vasodilation, myocardial ischemia and
damage, and possibly due to their use in patients without a
clear indication, rather than to the general principle of
inotropic therapy itself. This review will discuss the char-
acteristics of the patients with a potential indication for
inotropic therapy, the main data from registries and con-
trolled trials, the mechanism of the untoward effects of
these agents on outcomes and, lastly, perspectives with new
agents with novel mechanisms of action.
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Introduction
Since the introduction of digoxin into clinical practice,
inotropic agents have played a pivotal role in the treatment
of heart failure (HF). Enthusiasm, based on the patho-
physiological rationale for their administration, has been
progressively limited by the results of clinical research
with controlled trials and registries showing that their
administration may be attended by untoward effects and
increased mortality. This has led to a radical reassessment
of their role in the treatment of HF. Agents with novel
mechanisms of action are currently being tested, and fur-
ther improvements are likely to occur [1–6].
‘‘Epidemiology’’ of inotropic agents in acute heart
failure
Uncertainties regarding the indications and the benefits of
inotropic agents in HF are consistent with differences in their
use. Data from registries show a wide variability in the
prescription rates of inotropic drugs. The proportion of
patients receiving them ranges from 7% ,in the registry from
the Organized Program to Initiate Lifesaving Treatment in
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Hospitalized Patients with Heart Failure (OPTIMIZE-HF)
[7], to nearly 25% in the EuroHeart Failure Survey II (EHFS
II) [8] and in an Italian registry [9].
It is also interesting to note that the administration
of inotropic agents often does not comply with current
indications and guidelines [10–13]. In the Acute Decom-
pensated Heart Failure National Registry (ADHERE),
intravenous inotropic agents were administered to 8% of
patients with acute HF and preserved left ventricular (LV)
systolic function (versus 19% of the patients with reduced
LV systolic function) [14]. Low systolic blood pressure is
currently considered as a major criterion for selection of
patients for inotropic treatment. Despite this, inotropic
agents are often administered to patients with normal or
even high blood pressure. Among the 48,612 patients
enrolled in the OPTIMIZE-HF, 6.5, 4.5 and 3.2% were
treated with an inotropic agent in the systolic blood pres-
sure quartiles of 120–139 mmHg, 140–161 mmHg and
[161 mmHg, respectively [7]. In ADHERE, only 8% of
the total patients receiving inotropes had a systolic blood
pressure \90 mmHg, and the systolic blood pressure on
admission were 121 ± 27 mmHg and 124 ± 29 mmHg in
the patients receiving dobutamine and milrinone, respec-
tively [15]. Data from the EHFS II indicate that over 4% of
patients with hypertensive HF (with high BP defined as
[180/100 mmHg) received dobutamine or dopamine [8].
Thus, intravenous inotropic agents are still administered to
a significant proportion of patients admitted for acute HF,
but some of these patients may not have needed them.
Indications to inotropic agents
In theory, inotropic agents improve hemodynamic parame-
ters, increasing cardiac output and reducing left and right
ventricular filling pressure, through direct enhancement of
myocardial contractility. Accordingly, they are indicated for
the treatment of patients with both peripheral hypoperfusion
and fluid retention caused by impaired cardiac contractility.
Other criteria may be necessary to have an indication for
inotropic therapy (Table 1). First, hemodynamic impairment
must be present despite optimal medical treatment including
neurohormonal antagonists, diuretics and vasodilators.
Second, this hemodynamic impairment must be ‘‘clinically
meaningful’’, i.e. causing symptoms, clinical signs and,
more importantly, end-organ (kidney, liver) dysfunction.
When this occurs, it may be hypothesized that a correction of
hemodynamic abnormalities through inotropic therapy may
also favorably affect patient outcomes.
The indication for the appropriate administration of
inotropic agents requires that peripheral perfusion be ade-
quately assessed either by invasive hemodynamic moni-
toring or, more frequently, by clinical examination.
Clinical signs are generally relatively accurate for the
assessment of fluid overload. In contrast, peripheral
hypoperfusion is more difficult to detect. Hypotension is
the most frequently used and, ultimately, the best marker
for hypoperfusion and low cardiac output. Other signs of
hypoperfusion include a reduced pulse pressure, sleepy or
obtunded sensorium, cool extremities, hyponatremia, lab-
oratory signs of renal and/or hepatic dysfunction and
hemodynamic intolerance to angiotensin converting
enzyme (ACE) inhibitors and beta-blockers [16, 17].
These indications are in agreement with current guide-
lines. In the American College of Cardiology Federation
(ACCF)/American Heart Association guidelines, inotropic
agents are indicated to improve symptoms and end-organ
function in patients with low output syndrome, LV systolic
dysfunction and systolic blood pressure\90 mmHg despite
adequate filling pressure [13]. In the ESC guidelines,
patients with acute HF are stratified on the basis of their
systolic blood pressure at presentation, and inotropic agents
are indicated in patients with values B100 mmHg [12].
These indications, based on clinical assessment and
systolic blood pressure values, clearly limit the use of
currently available intravenous inotropic agents only to
those patients most likely to benefit from their adminis-
tration. Values of systolic blood pressure \90–100 mmHg
have been reported in less than 10% of the patients with
acute HF syndromes (AHFS)[7, 8, 15]. These patients have
increased in-hospital and postdischarge mortality rates with
a strong inverse correlation between systolic blood pressure
and survival [7]. The odds ratio (OR) of in-hospital death
increased by 21% for each 10-mmHg decrease in systolic
Table 1 Indications for inotropic therapy
1. Hemodynamic impairment with low cardiac output (i.e. cardiac index \2.0 Lt/min/m2) and increased left and/or right ventricular filling
pressures (i.e. pulmonary capillary wedge pressure [18–20 mmHg and right atrial pressure [10–12 mmHg)
2. Optimal medical treatment, including inhibitors of the renin-angiotensin system, aldosterone antagonists, when tolerated, and diuretics and
nitrates, when needed
3. Critical patient’s conditions caused by abnormal hemodynamics and including any of the following:
a. Severe exercise limitation
b. Diuretic resistant fluid overload
c. Kidney and/or liver dysfunction as shown by abnormal laboratory exams (serum creatinine, BUN, bilirubin, etc.)
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blood pressure below 160 mmHg in the OPTIMIZE-HF
registry [7], and in-hospital mortality rate was nearly 40%
among patients admitted in cardiogenic shock in the EHFS
II (3.9% of total), a greater than sixfold increase in risk
when compared to any other clinical profile of AHFS [8].
The criteria outlined previously apply to patients hos-
pitalized for acute HF. However, an indication for inotropic
therapy may also be found in outpatients with HF who have
persistent severe symptoms, frequent hospitalizations
caused by episodes of fluid retention and/or peripheral
hypoperfusion and/or signs of hepatic or renal dysfunction.
These patients include those in class IV of the New York
Heart Association (NYHA) classification as well as in stage
D of the ACCF/AHA classification [18]. Inotropic agents
may be indicated as bridge to heart transplantation or
mechanical assist device implantation or as palliation for
symptoms in end-stage HF [11–13, 19].
The recently introduced Interagency Registry for
Mechanically Assisted Circulatory Support (INTER-
MACS) has been developed to improve classification of
patients with advanced HF with potential indications to
mechanical circulatory support. Seven clinical profiles
have been described, from advanced NYHA class III
symptoms to cardiogenic shock, with 3 modifiers (arrhyth-
mias, need of temporary circulatory support and frequent
hospitalizations or emergency visits). Continuous intrave-
nous administration of inotropic agents is a hallmark of the
3 highest levels of severity, currently including 80% of the
patients on mechanical circulatory support [20]. This reg-
istry, as well as the HFA-ESC position statement [18],
highlights the need of therapies to support the failing heart
through either medical therapy or mechanical supports.
Prognostic impact and limitations of traditional
inotropic agents
Aims of treatment of patients with AHFS have been
extensively discussed in the last years. Radical changes
occurred and criteria for approval of new agents in AHFS
are now not very different from those for drugs for chronic
HF. Aims of treatment include an improvement in symp-
toms and/or outcomes [6, 10–13, 21]. Any new agent
cannot be approved in the absence of data showing its lack
of untoward effects on outcomes. However, most of the
current therapy for acute HF is based on drugs approved in
the past only on the basis of short-term hemodynamic and/
or symptomatic benefits that, as is the case of traditional
inotropic agents, have been often associated with untoward
effects on outcome. We will report herewith data regarding
the effects of inotropic agents on outcomes in patients with
either acute or advanced chronic HF and the potential
mechanisms of these untoward effects.
Acute heart failure: retrospective analyses
As is the case with most of the agents currently used for the
treatment of AHFS, inotropic agents are now used in clinical
practice despite the absence of data regarding their effects on
outcomes obtained by prospective, randomized controlled
studies. Thus, their relation with outcomes has been mainly
studied in retrospective analyses of registries. Abraham et al.
[22] have assessed the role of intravenous therapy on in-
hospital mortality in 15,230 patients with AHFS studied in
the ADHERE registry. Inotropic therapy was associated with
a twofold increase in the risk of in-hospital mortality when
compared to treatment with vasodilators. In-hospital mor-
tality rates were 12.3 and 13.9% in patients receiving mil-
rinone or dobutamine versus 4.7 and 7.1% in those receiving
nitrates or nesiritide, respectively [22]. The increased risk
associated with inotropic therapy remained significant after
adjustment for demographics and baseline clinical charac-
teristics by propensity score analysis.
Inotropic therapy also had an independent association
with an increased risk of in-hospital mortality in other reg-
istries [7, 9]. In the Evaluation Study of Congestive Heart
Failure and Pulmonary Artery Catheterization Effectiveness
(ESCAPE) trial, the administration of inotropic agents was
associated with an increase in 6-month risk of death and of
deaths or rehospitalizations (adjusted OR, 2.14, 95% CI:
1.10–4.15, P = 0.04; and 1.96, 95% CI: 1.37–2.82,
P \ 0.001, respectively). Patients with the worst outcomes
were those receiving both inotropes and vasodilators
(adjusted OR, 4.81, 95% CI: 2.34–9.90, P \ 0.001) [23].
The association between inotropic therapy and increased
mortality found in retrospective analyses may have dif-
ferent causes, in addition to direct untoward effects of these
agents on outcomes. First, although these associations
remained significant after adjustment for demographic and
baseline clinical variables by multivariable analysis, it
cannot be excluded that inotropic agents were administered
to the most severely ill patients. This selection bias may not
be adequately eliminated by statistical methods. For
example, in ADHERE, the median time to initiation of
inotropic therapy was of 18 h, compared with 1.3 h with
nitrates. This indicates that inotropes were often used as
rescue therapy in patients not responding to the other
agents and, thus, in more severe patients than those
receiving vasodilators [22]. Second, there may have been a
poor selection of patients treated with inotropes. As pointed
out before, a low systolic blood pressure is now considered
a main criterion for the indication to inotropic therapy.
However, a systolic blood pressure \90 mmHg was pres-
ent in only 8% of the patients receiving either dobutamine
or milrinone in ADHERE [15], and only 1,404 of 2,613
patients (54%) on inotropes had a systolic blood pressure
\120 mmHg in OPTIMIZE-HF [7]. It must, however, be
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noted that the increase in mortality associated with ino-
tropic therapy was found in all systolic blood pressure
quartiles patients groups, independent of blood pressure in
this registry [7].
Acute heart failure: prospective studies
Small, placebo-controlled studies have shown hemody-
namic and symptomatic improvements with a tendency
toward higher mortality risk after administration of either
dobutamine or phosphodiesterase type 3 inhibitors (PDE3-
I); such as amrinone, milrinone and enoximone) [23].
Results from small placebo-controlled trials with beta-
agonists, including dobutamine, and PDE3-I have been
combined in a meta-regression analysis showing a ten-
dency to an increase in mortality associated with dobuta-
mine or high-dose dopamine (OR 1.50, 95% CI: 0.51–3.92)
or PDE3-I [24].
In the Outcomes of a Prospective Trial of Intravenous
Milrinone for Exacerbations of Chronic Heart Failure
(OPTIME-CHF) trial, 951 patients admitted for exacerba-
tion of chronic HF caused by LV systolic dysfunction were
randomized to a 48-hour infusion of either milrinone or
placebo on top of standard therapy [25]. The primary
efficacy end-point of a reduction in the total number of
days of hospitalization for cardiovascular causes (or days
deceased) within 60 days postrandomization was not
reached (12.5 ± 14.0 vs. 12.3 ± 14.1 days for placebo and
milrinone, respectively, P = 0.71) [25]. No significant
differences were found between the placebo and the mil-
rinone group for in-hospital mortality (2.3 vs. 3.8%,
P = 0.19), 60-day mortality (8.9 vs. 10.3%, P = 0.41), or
combined 60-day death or readmission rates (35.3 vs.
35.0%, P = 0.92). Discontinuation rate of intravenous
infusion was higher in patients randomized to milrinone
compared to those on placebo (20.6 vs. 9.2%, P \ 0.001),
with higher rates of new-onset atrial fibrillation or flutter
(4.6 vs. 1.5%, P = 0.004), sustained hypotension (10.7 vs.
3.2%, P \ 0.001) and ventricular arrhythmias (3.4 vs.
1.5%, P = 0.06) [25]. A post hoc analysis of the OPTI-
MIZE-CHF has suggested that the increase in mortality
associated with milrinone administration was more pro-
nounced in patients with coronary artery disease with the
composite end-point of death and rehospitalization occur-
ring in 36 versus 42% of the ischemic patients treated with
placebo and milrinone, respectively, and no significant
differences between the two treatments among the nonis-
chemic patients (P = 0.01 for interaction) [26].
Advanced chronic HF
The effects of inotropic agents in these patients have been
investigated in several randomized controlled studies,
including some large-scale trials. The first suggestion of an
untoward effect of traditional inotropic agents on outcomes
came from an analysis of 471 patients enrolled in the
Flolan International Randomized Survival Trial FIRST
trial [27]. Intravenous continuous dobutamine infusion
(mean dose 9 lg/kg/min, range 5–12 lg/kg/min, median
duration of infusion, 14 days) was associated with an
increase in the incidence of the primary composite end-
point of the study and of mortality alone (70.5 vs. 37.1%;
P = 0.0001), and it was the strongest independent pre-
dictor of mortality (HR 2.189, P = 0.0001). Patients
receiving dobutamine infusions had more severe HF as
shown by the higher proportion of subjects in class IV (89
vs. 53% in class IV) and the lower systolic blood pressure
(100.5 vs. 108.0 mmHg). However, the association
between dobutamine infusion and poorer outcomes was
maintained after adjustment for baseline variables [27].
The Dobutamina nell’Insufficienza Cardiaca Estrema
(DICE) trial randomized 38 NYHA class III/IV patients
with severe hemodynamic impairment to a 48 hours/week,
6 months, infusion of low-dose dobutamine (2.5 lg/kg/
min) or placebo [28]. Intermittent dobutamine infusion was
well tolerated and was associated with hemodynamic
improvement and a trend toward lower hospitalization
rates. However, 5 of 19 patients died in the dobutamine
group versus 3 of 19 patients in the control group with also
a tendency to a shorter time to death (93 vs. 114 days) [28].
Long-term treatment with oral PDE3-Is in patients with
ACHF has been studied in several randomized controlled
trials. Oral milrinone increased morbidity and mortality in
1,088 patients with chronic HF when compared to placebo in
the pivotal Prospective Randomized Milrinone Survival
Evaluation (PROMISE) trial [29]. The greatest increase in
all-cause mortality was seen in the sickest patients with a
53% increase in risk with milrinone versus placebo (P =
0.006) in NYHA class IV subjects when compared to a 28%
increase in risk in the overall population (P = 0.038) [29].
The Vesnarinone Trial enrolled 3,833 patients (approxi-
mately 14% in NYHA class IV) randomized 1:1:1 to pla-
cebo, vesnarinone 30 mg and vesnarinone 60 mg. Quality of
life significantly improved in the 60-mg vesnarinone group
when compared to placebo at 8 and 16 weeks (P \ 0.001
and P = 0.003, respectively). In contrast, over a mean fol-
low-up of 286 days, there was a dose-dependent increase in
all-cause mortality: 18.9% in the placebo group versus 21.0
and 22.9% in the 30-mg and the 60-mg vesnarinone group,
respectively. High-dose vesnarinone was associated with a
higher risk of sudden death (12.3 vs. 9.1% in the placebo
group, OR, 1.35, 95% CI: 1.08–1.69). Mortality data as well
as changes in quality of life were similar in the placebo group
and in the 30-mg vesnarinone group [29].
The Pimobendan In Congestive Heart Failure (PICO)
trial randomized 317 patients with stable symptomatic
246 Heart Fail Rev (2009) 14:243–253
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NYHA class II–III HF to placebo or pimobendan 2.5 or
5 mg daily [30]. The primary outcome was exercise time
(by bicycle ergometry) at 4, 12 and 24 weeks after the start
of the study. Both pimobendan dosages improved exercise
duration by 6% (P = 0.03 and 0.05, respectively) after
24 weeks with no change in peak oxygen consumption and
on quality of life, but there was also a trend to an increased
risk of death (OR 1.8, 95%CIs: 0.9–3.5 for pimobendan
versus placebo) [31]. Long-term administration of enoxi-
mone at high doses (C100 mg tid) has also been associated
with increased mortality [32].
The consistent results of randomized clinical trials have
led to slowing in the development of inotropic agents for
the chronic treatment of severe HF. However, some issues
remain. First, a few patients may not be stabilized by
standard treatment and may still need chronic inotropic
support as bridging to heart transplantation or a ventricular
assist device implantation and/or as symptomatic palliation
for end-stage disease. Such an indication is also accepted in
the guidelines [11–13] and is often accomplished through
intermittent intravenous therapy with either dobutamine or
milrinone [33].
Second, concomitant administration of beta-blocking
agents, ICDs implantation, as well as the administration of
lower doses might allow better tolerance and avoid the
effects on mortality and disease progression of even
traditional inotropic agents [32, 34]. This hypothesis has
been tested in placebo-controlled trials of low-dose (i.e.
25–50 mg tid) oral enoximone administration to patients
on intermittent inotropic therapy [35] and with advanced
chronic HF on optimal oral medical treatment in the
Studies of Oral Enoximone Therapy in Advanced Heart
Failure (ESSENTIAL) trials, respectively [36]. Despite
some favorable trends, these trials failed to show beneficial
effects with respect to freedom from death or reinitiation of
intravenous therapy, in the first study [35], and with respect
to time to death or rehospitalization in the second, larger
(1,854 patients), trial [36]. It must be noted, however, that,
for the first time, these trials showed a lack of untoward
effects on mortality as well as favorable trends in some
end-points such as a trend to lower mortality and reinsti-
tution of intravenous therapy over the 182-day study period
(HR, 0.76, 95%CIs: 0.55–1.04) in the trial in patients on
inotropic support [35], and a tendency to better results in
the 6-min walk test in the patients with more severe HF
enrolled in ESSENTIAL [36].
Mechanisms of the untoward effects on outcomes
The mechanisms of the untoward effects of traditional
inotropic agents on survival are multiple but seem mainly
related to tachyarrhythmias and myocardial ischemia and
damage (Table 2). Atrial and ventricular tachyarrhythmias
are often present in patients with AHFS and ACHF.
Though they may not have an independent prognostic role
in patients with chronic HF they may contribute to the poor
survival of patients in unstable conditions through further
worsening of hemodynamics and increased myocardial
oxygen consumption. Traditional inotropic agents, espe-
cially dobutamine and PDE3-Is, have concomitant vasod-
ilating effects. Though this vasodilation may be beneficial
in patients with normal to high blood pressure, through the
effects of afterload reduction, this may have deleterious
consequences when these agent are given to patients with
low to normal blood pressure. Excessive peripheral vaso-
dilation may, in fact, cause coronary hypoperfusion and
further myocardial damage, a mechanism likely contrib-
uting to the poor prognosis of patients with AHFS [6, 37].
In the patients with AHFS, the administration of ino-
tropic agents may also favor myocardial ischemia and
damage through increased myocardial oxygen consumption
caused by tachycardia and increased myocardial contrac-
tility. Traditional inotropes also decrease myocardial effi-
ciency thus increasing oxygen expenditure for any amount
of myocardial work. As shown in an experimental model of
myocardial infarction, inotropic stimulation with dobuta-
mine may cause necrosis in areas of myocardial hiberna-
tion with further loss of vital myocardium [38]. The
negative interaction between inotropic agents and coronary
artery disease is also demonstrated by the increase in
mortality in patients with ischemic cardiomyopathy
receiving milrinone in the OPTIME-CHF trial [26].
All the mechanisms related to the untoward effects of
inotropic agents on outcomes seem therefore to be related
to cAMP stimulation with a consequent rise in intracellular
calcium concentrations in the cardiomyocytes and to
peripheral vasodilation. Unfortunately, this effect is the
same mechanism by which these agents increase inotropy.
Consequently, with most current therapies, the mechanism
of the beneficial hemodynamic effects is the same cause of
the adverse effects. Inotropic agents acting independently
from these pathways should not necessarily have untoward
effects on survival and, perhaps, we have a good starting
example with digitalis therapy.
Table 2 Limitations of inotropic agents
Tachyarrhythmias
Increased ventricular arrhythmias
Increased ventricular rate in atrial fibrillation
Myocardial ischemia
Hypotension—coronary hypoperfusion
Increased heart rate and myocardial contractility—increased
myocardial oxygen consumption
Direct myocyte toxicity—intracellular calcium overload
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The case of digoxin
The evidence on the beneficial properties of digoxin in the
setting of HF has been gathered from over 200 years of
clinical and experimental research [39]. Digoxin acts
through inhibition of the sarcolemmal Na–K ATPase pump
thus leading to increased intracellular sodium that is then
exchanged with calcium. The increase in intracellular cal-
cium causes the inotropic effect of the drug.
The beneficial hemodynamic effects of digoxin are
attained in the absence of any hypotension or tachycardia
and with associated favorable effects on neurohormones
including a decrease in the sympathetic drive and renin-
angiotensin-aldosterone activation and an increase in vagal
stimulation [39]. Despite these favorable results, few
studies have assessed the effects of digoxin in patients with
acute HF [40].
Conversely, digoxin use is rather common in patients
with chronic HF (approximately 50–65% of patients
overall, range 55–91%) [39]. The landmark Digitalis
Investigators Group (DIG) trial assessed the effects of
digoxin on mortality in a total of 7,788 patients with
chronic stable HF (*85% NYHA class II–III) randomized
to placebo or digoxin with treatment targeting to serum
digoxin concentrations 0.8–2.5 ng/ml [41]. The study
included 6,800 HF patients with EF B 45% (DIG-Main)
and 988 patients with EF [ 45% (DIG-Ancillary). The
median daily dose of digoxin was 0.25 mg. Although
digoxin did not reduce the primary end-point of all-cause
mortality during 37 months of follow-up, it did signifi-
cantly reduce HF-related deaths or rehospitalization [41].
Further data analyses showed the pivotal role of the
serum digoxin concentrations achieved during treatment.
This issue was first addressed in a post hoc analysis by
Gheorghiade et al. This study showed that while the effects
of digoxin on LV function are dose dependent, increasing
serum digoxin concentrations have no relation with chan-
ges in exercise tolerance and neurohormonal parameters
[42]. In a post hoc analysis of the DIG trial restricted to
male patients with LV EF B 45% (n = 3,782), there was a
positive correlation between increased mortality and serum
digoxin concentrations [43]. Patients with the lowest con-
centrations (0.5–0.8 ng/ml) showed the lowest mortality
rate with digoxin compared to placebo (6.3% decrease,
95% CI: 2.1–10.5%), with no effect at concentrations of
0.9–1.1 ng/ml and a higher mortality with digoxin in
patients with digoxin concentrations [1.2 ng/ml (11.8%
increase, 95% CI: 5.7–18.0%). Lower serum levels were
later reported to be consistently associated with reduced
mortality and hospitalization in all the patients enrolled in
the DIG trial regardless of EF during 40-month median
follow-up [43]. Another independent analysis confirmed
the ‘‘bidirectional relation’’ between serum digoxin
concentrations and mortality with reduced mortality at
values of serum digoxin concentrations of 0.5–0.9 lg/kg/
min [44].
It is also possible that follow-up duration, actually
longer than in most of other controlled trials in HF, influ-
enced the results. A recent post hoc analysis has shown that
digoxin reduces 1-year all-cause mortality (HR for digoxin
0.87, 95% CI: 0.76–0.995, P = 0.043), cardiovascular
mortality (HR, 0.87, 95% CI: 0.75–1.01, P = 0.072), HF
mortality (HR, 0.66, 95% CI: 0.52–0.85, P = 0.001) and
all-cause hospitalization (HR, 0.89, 95% CI: 0.83–0.96,
P = 0.002) in patients from the DIG trial irrespective of
digoxin concentration [45].
Thus, digoxin administration targeted to low serum
levels may be associated with hemodynamic and clinical
improvements, reduced morbidity and possibly increased
survival. Implementation of this agent is, however, limited
by its narrow risk to benefit ratio. Currently, recommended
target therapeutic ranges are lower than in the past and than
those aimed to in the DIG trial, so that potential side-effects
related to digoxin toxicity are supposedly less frequent than
previously observed. Lastly, digoxin, the oldest drug cur-
rently used for the treatment of HF, may be the agent to
open new tracks for the research on inotropic agents. We
will briefly summarize herewith data regarding more recent
inotropic agents with novel mechanisms of action.
New mechanisms, new inotropic agents
A detailed description of these agents is beyond the aims of
this review. However, we will summarize some of the main
results and perspectives with respect to some of them.
Levosimendan
Levosimendan is a calcium sensitizing agent with two
complimentary mechanisms of action, enhanced cardiac
troponin C sensitivity to intracellular calcium and periph-
eral vasodilation through opening of smooth muscle ATP-
dependent potassium channels, as well as some potential
PDE3-I activity. These mechanisms mediate its inotropic
and vasodilating effects, respectively. A detailed descrip-
tion of the mechanisms of action and clinical effects of
levosimendan is beyond the aims of this review and thor-
ough reviews are available [46, 47].
The recent Randomized Multicenter Evaluation of
Intravenous Levosimendan Efficacy Versus Placebo in the
Short-Term Treatment of Decompensated Heart Failure
(REVIVE) trial, consisting of 2 consecutive phases,
REVIVE-1 (n = 100) and -2 (n = 600), investigated the
effect on levosimendan versus placebo on primary com-
bined end-points. Particularly, the primary end-point of
248 Heart Fail Rev (2009) 14:243–253
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REVIVE-II was a composite based on patients’ self-rating
as moderately or markedly improved at 6 h, 24 h and
5 days in the absence of any criteria for worsening [48]. In
the REVIVE-2, despite a significant improvement of the
primary end-point in patients randomized to levosimendan
(overall P = 0.015), active drug treatment was associated
with higher rates of adverse effects, including hypotension
(49 vs. 36% on placebo), ventricular tachycardia (24 vs.
17% on placebo) and atrial fibrillation (4 vs. 1%). Mortality
at 90 days was of 15% in the levosimendan group versus
12% with placebo (P = 0.210) [48].
All-cause mortality was the primary end-point of the
Survival of Patients with Acute Heart Failure in Need of
Intravenous Inotropic Support (SURVIVE) study in which
levosimendan was compared to dobutamine [49]. In
SURVIVE, 1,327 patients hospitalized for HF were ran-
domized to levosimendan (12 lg/kg loading dose followed
by 1-h at 0.1 lg/kg/min up-titrated to 0.2 lg/kg/min for the
following 23 h) or dobutamine (starting dose 5 lg/kg/min)
[49]. Mortality at 180 days was similar in the two treatment
groups (26 vs. 28%, HR for levosimendan 0.91, 95% CI:
0.74–1.13, P = 0.40). The lack of any survival benefit with
levosimendan, compared with dobutamine, has been
ascribed to the associated vasodilatory action of levosim-
endan, when administered at the doses used in this trial
[49]. Other contributing factors may have been tachycardia
with levosimendan and unsatisfactory patients selection
with inclusion of patients with new-onset AHF (mortality
was of 26% in the levosimendan versus 17% in the
dobutamine group, HR, 1.61, 95% CI: 0.80–3.25, P = 0.05
for interaction with previous HF) [49].
Despite interesting new mechanisms of action and
favorable results in preliminary trials, more recent studies
have thus failed to yield conclusive results regarding the
risk to benefit ratio of levosimendan in patients with AHFS.
Istaroxime
Istaroxime is a novel agent, with both inotropic and lusitropic
effects. It inhibits the sarcolemmal Na–K ATPase, thus
increasing cytosolic calcium and stimulating sarcoplasmic
reticulum calcium ATPase isoform-2 (SERCA-2). This last
action enhances calcium reuptake by the sarcoplasmic
reticulum, favoring myocardial relaxation. Greater sarco-
plasmic reticulum calcium reuptake during diastole also
leads to greater calcium available for release at the next
systole and, thus, has also a positive inotropic effect [50, 51].
In an experimental canine model of ischemic advanced
chronic HF, continuous infusion of escalating doses of ist-
aroxime (0.5, 1.0, 2.0, 3.0, and 5.0 lg/kg/min) increased LV
EF in a dose-dependent fashion from 0.25 ± 0.01% to
0.42 ± 0.02% at the highest dose (P \ 0.05), with no
increase in myocardial oxygen consumption [50]. Diastolic
parameters were also improved, and no arrhythmias were
detected. A recently published study assessed the hemody-
namic effects of istaroxime in 120 patients admitted for AHF
with left ventricular ejection fraction B35% (mean 27 ±
7%) and low systolic blood pressure (116 ± 3 mmHg)
randomized 3:1 to a 6 h continuous infusion of 3 different
doses of istaroxime (0.5, 1.0 and 1.5 lg/kg/min) or placebo.
[52]. Istaroxime infusion was associated with a reduction in
pulmonary capillary wedge pressure, the primary end-point
of the study (P \ 0.05 for all 3 doses vs. placebo) and an
increase in stroke work index (at 1.5 lg/kg/min). Unlike
traditional intravenous inotropic agents, istaroxime was
associated with a dose-dependent reduction in heart rate and
an increase in systolic BP [52]. Hemodynamic and echo-
cardiographic analyses of these data have confirmed findings
from the previous study, showing a decrease in left ventric-
ular volumes and an improvement in left ventricular ejection
fraction with istaroxime administration and has shown its
lusitropic effects with an increase in the lateral mitral
annulus early diastolic velocity (E0), a prolongation of the
E-wave deceleration half-time and a decrease in the E/A ratio
of transmitral flow velocity [53].
Thus, istaroxime has a unique hemodynamic profile with
an improvement in left ventricular diastolic function and a
reduction in ventricular filling pressure attended by slow-
ing of heart rate and no change or an increase in systolic
blood pressure.
Cardiac myosin activators
These agents directly target myocardial myosin ATPase,
increasing the rate of effective myosin cross-bridge forma-
tion, and hence the duration and amount of myocyte con-
traction with increased myocyte energy utilization, and no
effect on intracellular calcium or cAMP [4, 54]. Active
research in the recent past has led to the development of the
selective cardiac myosin activator CK-1827452, now known
as omecamtiv mecarbil, the first agent to be tested in humans
[54]. In a pivotal phase I trial by Teerlink et al. on 34 healthy
volunteers, omecamtiv mecarbil, at the dose of 0.5 mg/kg/
min given as a 6-h continuous infusion, induced a 6.8% and a
9.2% absolute increase in EF and in fractional shortening,
respectively (P \ 0.0001 for both) [54]. Systolic ejection
time was prolonged by a mean 84 ms (P \ 0.0001). These
findings, as well as those observed in experimental models,
are consistent with a unique positive inotropic effect elicited
through direct increase in systolic ejection time rather than
through increase in contraction velocity. The first Phase II
trial of omecamtiv mecarbil was a multi-center, double-
blind, randomized, placebo-controlled study in a total of 45
stable heart failure patients treated with an ACE inhibitor (or
ARB) and a beta-blocker, ±diuretics, exposed to a total of
151 dosing periods divided among 5 cohorts. In Cohorts 1–4,
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patients each received four treatments: three escalating doses
of omecamtiv mecarbil and one placebo treatment that was
randomized into the dosing sequence to maintain blinding.
Each of the four treatments was at least 1 week apart. In
Cohort 5, patients received two 72-h treatments, omecamtiv
mecarbil and placebo in a double-blind crossover fashion.
This study confirmed the findings of the Phase I study, with
concentration-dependent increases in the systolic ejection
time accompanied by improvements in fractional shortening,
stroke volume, ejection fraction with associated decreases in
heart rate. No difference in these effects has been found
between patients with ischemic and nonischemic cardio-
myopathy. To date, this agent has been safe and well toler-
ated. Additional Phase II trials are currently underway in
patients with HF [54] and ischemic heart disease. Cardiac
myosin activators may be expected to play an active role in
the quest for the ideal, safe and effective inotropic agent, and
the availability of a highly bioavailable oral formulation
suggests that these benefits may be extended to therapy of
chronic heart failure.
Metabolic modulators
Cardiac performance may also be enhanced by modifying
substrate utilization from free fatty acids to more efficient
fuels like glucose and lactate. This may result in a net
10–15% saving in oxygen consumption [4, 5]. Metabolic
modulators have been extensively studied and are currently
used in patients with ischemic heart disease, specifically
stable angina. Among others, ranolazine, perhexiline and
trimetazidine have also been investigated in experimental
and clinical HF showing beneficial effects [4]. Ranolazine
has shown favorable hemodynamic effects both acutely
[55] and chronically, on LV remodeling. In an experi-
mental model of microembolization-induced HF it was
associated with prevention of the increase in end-diastolic
and end-systolic left ventricular volumes and an increase in
LV ejection fraction [56, 57].
Trimetazidine and perhexiline administration have been
associated with symptomatic improvements and beneficial
effects on quality of life, exercise tolerance and left ven-
tricular systolic function [58, 59].
SERCA 2A activators
Reuptake of calcium into the sarcoplasmic reticulum
occurs via SERCA2a, which is downregulated in HF. This
accounts for the increase in free intracytoplasmatic calcium
in the cardiomyocytes, a major responsible for impaired
cardiac function and tachyarrhythmias. Hence, SERCA2a
is now a major target for treatment of both HF with pre-
served LV ejection fraction and HF with low LV ejection
fraction. One biological agent under development in this
category is MYDICAR, an adeno-associated viral-vector
carrying the gene for SERCA2a. The drug is being studied
now and is administered by intracoronary injections to
patients with end-stage heart failure (Calcium Up-Regula-
tion by Percutaneous Administration of Gene Therapy In
Cardiac Disease trial [CUPID]). The results of this phase 2
double-blind study will be known in 2010 [60, 61].
In addition to gene therapy, a class of novel small
molecules, acting as allosteric compounds, is under
development and in preclinical models have been found to
modulate SERCA2a activity and increase Vmax and con-
tractility without increasing energy utilization, making
them important candidates as new IV inotropic drugs.
Clinical studies are expected to start in 2010.
Conclusions
Many studies have consistently shown that current inotropic
therapies are associated with increased mortality in patients
with both acute and chronic HF. Tachyarrhythmias and
myocardial damage, exacerbated by hypotension and
increased myocardial oxygen consumption, are the most
likely mechanisms of the untoward effects of these agents.
According to this hypothesis, the unfavorable effects on
outcomes are mechanism-dependent and not intrinsic to
changes in myocardial contractility. Recently published
guidelines have needed to account for the mechanism of
action and the benefit to risk profiles of these agents.
Dobutamine, milrinone (and other PDE3-Is) and levosim-
endan are all potent vasodilators, and consequently, their
guideline recommended use in patients with systolic blood
pressures less than 90 mmHg presents significant clinical
challenges. All of these agents have been associated with
significant and life-threatening adverse effects, such that
their recommended use is limited only to those patients at
high risk for poor outcomes, and it is clearly difficult to
improve survival in them.
However, it is important to recall that over half of the
greater than 1.1 million hospitalizations for heart failure in
the US alone are in patients with reduced systolic function.
Thus, there is still a potential indication to inotropic ther-
apy. Digoxin, the oldest inotropic agent used in clinical
practice, has not been associated with worse outcomes in
the controlled trials. More studies regarding its efficacy and
tolerability in the current era of HF treatment are war-
ranted. New, potentially safer, positive inotropic agents,
such as istaroxime and omecamtiv mecarbil, may increase
dramatically the number of patients who may benefit from
this type of therapy. New agents with more favorable
effects on myocardial perfusion and cardiac efficiency are
likely going to open new pathways to improve quality of
life and outcomes of patients with advanced HF.
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